Evommune
Palo Alto
About Evommune
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $474.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nyse:EVMN
- Website: evommune.com
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/evommune-75384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.